Febuxostat cardiovascular safety trial raises more questions than answers

An FDA-mandated cardiovascular safety trial of gout drug febuxostat (Adenuric) has found an unexpected increase in all-cause mortality but no difference in major cardiovascular events, compared to allopurinol. The CARES trial was initiated at the behest of the FDA to investigate a modest increase in cardiovascular events  seen in earlier trials of febuxostat compared to ...

Already a member?

Login to keep reading.

© 2021 the limbic